BKB Growth details 224,719 Verrica (VRCA) Series B warrant rights

Rhea-AI Filing Summary

BKB Growth Investments, LLC reported its beneficial ownership of derivative securities of Verrica Pharmaceuticals Inc. through an amended ownership statement. The filing lists Series B Warrants, immediately exercisable, for 224,719 shares of Verrica common stock at an exercise price of $13.35 per share, expiring on 11/22/2029.

The warrants include a cap that prevents exercises that would push BKB Growth’s beneficial ownership above 19.99% of Verrica’s outstanding common stock after the exercise. The amendment explains that the original exercise price did not reflect Verrica’s 1-for-10 reverse stock split that took effect on July 24, 2025.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BKB Growth Investments, LLC

Role 10% Owner

Type	Security	Shares	Price	Value
holding	Series B Warrants (right to buy)	--	--	--

Holdings After Transaction: Series B Warrants (right to buy) — 224,719 shares (Direct)

Footnotes (1)

1. Immediately exercisable. The Reporting Person will not be entitled to exercise any portion of a Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 19.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. The exercise price on the original Form 3 did not account for the 1-for-10 reverse stock split of the Issuer's common stock that went into effect on July 24, 2025.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

BKB Growth Investments, LLC

(Last) (First) (Middle)

C/O TIGER LILY CAPITAL, LLC

200 GARRETT STREET, SUITE S

(Street)

CHARLOTTESVILLE VA 22902

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/25/2025

3. Issuer Name and Ticker or Trading Symbol
Verrica Pharmaceuticals Inc. [ VRCA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)
01/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Warrants (right to buy)	(1)(2)	11/22/2029	Common Stock	224,719	$13.35(3)	D

Explanation of Responses:

1. Immediately exercisable.

2. The Reporting Person will not be entitled to exercise any portion of a Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 19.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.

3. The exercise price on the original Form 3 did not account for the 1-for-10 reverse stock split of the Issuer's common stock that went into effect on July 24, 2025.

	BKB Growth Investments, LLC, By: Tiger Lily Capital, LLC, its manager By: /s/ Paul Manning, its manager	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BKB Growth Investments report in this Verrica (VRCA) Form 3/A?

BKB Growth Investments, LLC reported beneficial ownership of Series B Warrants linked to Verrica common stock. The warrants are immediately exercisable, cover 224,719 shares, and are documented in an amended initial ownership report reflecting corrected terms after a reverse stock split.

How many Verrica (VRCA) shares are underlying BKB Growth’s Series B Warrants?

The Series B Warrants held by BKB Growth Investments, LLC are exercisable for 224,719 shares of Verrica Pharmaceuticals common stock. These derivative securities are listed in the filing’s Table II as immediately exercisable and expiring on November 22, 2029, subject to a 19.99% ownership cap.

What are the key terms of BKB Growth’s Series B Warrants in Verrica (VRCA)?

The Series B Warrants are immediately exercisable at an exercise price of $13.35 per share and expire on November 22, 2029. They relate to 224,719 shares of Verrica common stock and include a 19.99% beneficial ownership limitation upon exercise.

What is the 19.99% ownership limitation mentioned for Verrica (VRCA) warrants?

The filing states BKB Growth cannot exercise any portion of a Series B Warrant if, after exercise, its aggregate beneficial ownership would exceed 19.99% of Verrica’s outstanding common stock, effectively capping how many shares can be obtained through warrant exercises.

Why was this Verrica (VRCA) Form 3/A filed as an amendment?

The amendment explains that the original exercise price for the Series B Warrants did not account for Verrica’s 1-for-10 reverse stock split, which became effective July 24, 2025. This filing reflects the corrected $13.35 exercise price after that corporate action.

Who signed the Verrica (VRCA) Form 3/A for BKB Growth Investments?

The Form 3/A was signed for BKB Growth Investments, LLC by Tiger Lily Capital, LLC, its manager, and then by Paul Manning as manager of Tiger Lily Capital, LLC. The signature date on the document is February 2, 2026, confirming the reported ownership information.